Group 1 - The company has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL PF in Indonesia, which is an innovative drug licensed by Tenpoint Therapeutics for the treatment of presbyopia [1] - Under the agreement, the company grants PT Ferron exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL PF in Indonesia, and will receive an upfront payment along with potential milestone payments based on specific achievements [1] - The developer of BRIMOCHOL PF, Tenpoint, announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026 [1] Group 2 - BRIMOCHOL PF is a preservative-free, experimental eye drop intended for correcting near vision loss due to aging, and is part of a multi-center, randomized, double-blind study involving 629 participants across 47 trial centers in the U.S. [2] - The study compares the safety and efficacy of BRIMOCHOL PF against other formulations, including a single-agent therapy and a carrier eye drop [2] Group 3 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is recognized as one of the top 15 largest pharmaceutical companies in Indonesia according to IQVIA's data [3] - The company has received recognition from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency and Portugal's National Authority of Medicines and Health Products, enhancing its credibility [3] - PT Ferron is strengthening its market influence and operational capabilities through a diversified product portfolio, advanced production capabilities, and strong strategic partnerships [3]